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varieties (Cosgrove et al., 2004), the 
histone variants H3.3 and H2A.Z (Jin 
and Felsenfeld, 2007), and chroma-
tin-associated proteins that bind to 
modified histones or to methylated 
DNA (Li et al., 2007). These effec-
tors of nucleosome stability have 
often been referred to as “marks,” 
leaving open the question of how 
marking can result in gene activa-
tion or repression and epigenetic 
maintenance of these states. But if 
these diverse chromatin modifiers 
act by simply increasing or decreas-
ing nucleosome stability, then we 
may be much closer to a precise 
molecular understanding of epigen-
etic inheritance in development and 
disease.
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The frequency of in situ carcinomas has been rising since the introduction of mammographic 
screening. The management of patients with preinvasive disease remains difficult due to our lack of 
ability to accurately predict which patients will recur and progress to invasive carcinoma. Although 
some factors, such as lesion size and extent of margin clearance, are strong predictors of recurrence, 
many patients are still under- or overtreated. In this issue of Cancer Cell, Gauthier and colleagues 
suggest that abrogated response to cell stress measured by analysis of p16 and the proliferation 
marker Ki67 accurately predicts recurrence in ductal carcinoma in situ.Ductal carcinoma in situ (DCIS) is a 
heterogeneous disease, diagnosed 
with increasing frequency since the 
introduction of the mammographic 
screening program (Hofvind et al., 
2007). A number of classification sys-
tems have been proposed, primarily 
based on nuclear morphology. The 
type of DCIS, lesion size, and most 
importantly, distance to excision 
margin have been shown to be strong 
predictors of recurrence (MacDonald 
et al., 2005). Approximately half of 
recurrences remain in situ, while half will be invasive. Patients with invasive 
carcinoma are at risk of metastases, 
and hence this represents a signifi-
cant event for the patient.
Several studies have demonstrated 
that the risk of in situ and invasive 
recurrence is greater for high-grade 
compared to low-grade DCIS. This 
would suggest that more aggressive 
therapy is indicated for high-grade 
lesions, and although the best treat-
ment for DCIS is still uncertain, there 
is little doubt that a margin ≥10 mm, 
endocrine therapy, and radiotherapy Cancer Cell 12, following excision reduces the risk of 
recurrence (MacDonald et al., 2005; 
Burstein et al.,2004). Nonetheless, it 
is clear that our ability to accurately 
predict which patient will recur is 
limited, leading to under- or over-
treatment.
In the current issue of Cancer Cell, 
Gauthier et al. (2007) suggest that a 
simple panel of markers may solve 
that problem. DCIS with high P16+ 
and/or COX2+ and high Ki67+ con-
fers a significant risk of subsequent 
in situ and invasive recurrence. What November 2007 ©2007 Elsevier Inc. 409
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should we all be rushing to 
add this panel to our routine 
practice?
Three factors are thought 
to be important in the 
development of cellular 
senescence: DNA damage, 
telomere shortening, and 
suppression of the INK4a/
ARF locus (Collado et al., 
2007). Collectively, these 
mechanisms protect from 
uncontrolled proliferation 
and hence tumor forma-
tion. The authors argue that 
mechanisms that lead to 
abrogation of such a path-
way would contribute to 
tumorigenesis and may help 
to predict DCIS that is likely 
to progress. They studied the expres-
sion of p16 (INK4a) in a cohort of 70 
DCIS, 38 that did not progress and 
32 with recurrent DCIS or invasive 
carcinoma. Eighteen of seventy DCIS 
lesions had high p16+ (≥25% cells), 
and this was independent of grade 
and ER (estrogen) status. Interest-
ingly, the p16 expression did not pre-
dict for subsequent behavior.
p16 overexpression can occur 
under two different circumstances, 
either as a result of cellular stress on 
a background of a functional p16/RB 
pathway leading to senescence or 
on a background of suppressed or 
compromised RB pathway, where it 
is overexpressed due to loss of nega-
tive feedback. Hence, despite the 
same end result (P16+), the effect on 
cell proliferation would be quite differ-
ent. Staining for Ki67, a proliferation 
marker, demonstrated 26/70 DCIS 
with a high Ki67 index (>10%). Of the 
18 cases with high p16+, 8 also had 
high Ki67+, and all had subsequent 
recurrence, 5 of these with invasive 
disease. Of the ten p16+ DCIS with 
low Ki67+, only one DCIS developed 
a recurrence. Hence, DCIS that prog-
ress appear to have a compromised 
RB pathway.
A number of groups have demon-
strated that the pathological grade 
and genetic changes in the recurrence 
mirror the primary DCIS (Millis et al., 
2004). The authors hypothesized that 
the high p16+/Ki67+ seen in DCIS 
would therefore also be a hallmark 
of invasive carcinoma. In a set of 130 
invasive cancers analyzed for expres-
sion profiling, the authors found an 
association between p16 mRNA 
expression and the “basal-like” breast 
cancers. They also demonstrated that 
these basal cancers had low levels of 
RB, high E2F3, high Cyclin E, and low 
Cyclin D. Further, the authors noted 
that COX2 overexpression was also 
a feature of basal cancers. Interest-
ingly, like p16, COX2 expression in 
the DCIS cohort did not predict for 
recurrence on its own but was predic-
tive if combined with Ki67 status. The 
authors went on to demonstrate that 
overexpression of COX2 in high p16+/
Ki67+ DCIS was a consequence of the 
deregulated p16/RB pathway.
Hence, the authors conclude that 
high p16+ and/or COX2+ and Ki67+ 
predict for recurrence and that this 
phenotype is that of invasive basal 
cancers. Although the numbers of 
cases studied is very small for sub-
set analysis, the authors make the 
point that 6/26 high-grade DCIS had 
a high p16+/Ki67+ phenotype, and all 
developed recurrences, suggesting 
that this panel may also be able to 
stratify high-grade lesions into clini-
cally meaningful groups.
In a further twist to the story, the 
authors report that half their cases of 
DCIS with a high p16+ and/or COX2+ 
and Ki67+ were positive for 
ER, despite the finding that 
this phenotype is associ-
ated with a basal invasive 
cancer, a tumor type that 
is often though not always 
ER negative. Since the “tri-
ple-positive” DCIS in their 
hands is invariably linked 
to a subsequent recurrence 
(often invasive), the authors 
argue that basal like tumor 
may arise from both ER+ 
and ER− DCIS. There is 
evidence in the literature, 
although little highlighted, 
that basal cancers are het-
erogeneous with relation 
to prognosis and are not 
universally “bad” (Fulford 
et al., 2007). Perhaps here 
we have a hint regarding the biology 
underlying this heterogeneity. The 
rush to assign histogenetic relation-
ships (“basal cancers arise from basal 
cells”) may also be too simplistic, as 
it does not take into account cellular 
plasticity (Gusterson et al., 2005).
A larger series may help in refin-
ing the role of ER in the pathogenesis 
of DCIS and its progression to inva-
sive cancer. The hypothesis that ER+ 
DCIS with an abrogated response 
may be “dead-end” lesions is unlikely, 
as there is compelling evidence that 
the stroma may play a significant role 
in disease progression (Orimo et al., 
2005) and that, given the same start-
ing cell population, the conditions in 
which the cells grow can substantially 
alter the type of tumor that develops 
(Ince et al., 2007).
So should we incorporate this 
“triple test” into our routine clinical 
practice? Clearly the study is tanta-
lizing but at this stage very small and 
needs validating in a larger set as 
well as in prospective studies. In this 
small cohort it appears to be highly 
predictive; however, the panel does 
not identify all patients that recurred, 
and hence the true sensitivity and 
specificity of the test are unclear.
It is implicit but not always intuitive 
that the lesion studied is not the one 
that progresses, since it is out of the 
patient. The role of the biological path-
way in any lesion of equivalent grade or 
figure 1. Tumor Recurrence: DcIs versus LcIs
Ductal carcinoma in situ (DCIS) (A) is mostly a segmental disease and 
can be removed by local excision. Risk factors for recurrence include 
grade, size, and margin of excision. The paper by Gauthier et al. sug-
gests that high p16+ and/or high COX2 and high Ki67+ predict for in 
situ and invasive recurrence (B). In contrast, lobular carcinoma in situ 
(LCIS) (C) is a multifocal and in some patients a bilateral disease and 
hence cannot be removed by segmental excision. Although the risk of 
recurrence is skewed to the ipsilateral breast, some women will get 
invasive cancer in the opposite breast; hence, management is even 
more problematic.410 Cancer Cell 12, November 2007 ©2007 Elsevier Inc.
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Previewsworse left behind, or in normal tissues, 
remains unclear. Further, the study 
does not address the issue of hetero-
geneity within the same sample.
There is also a need to correlate 
the findings with clinicopathological 
features and to be able to carry out 
subset analysis, in particular expand-
ing the analysis of the high-grade/
high-p16/high-Ki67 DCIS. This issue 
also highlights very clearly that a 
combination of pathological, clinical, 
and molecular factors may ultimately 
reveal more powerful and robust mea-
sures for disease classification than 
any one modality alone (Rosai, 2007).
The ability to predict the outcome 
of an in situ cancer at the time of pri-
mary diagnosis would make a huge 
impact in clinical practice, especially 
as the frequency of the lesions is rising 
due to mammographic screening. The NOTCH1 encodes a transmembrane 
receptor that undergoes a series of 
activation steps upon ligand binding, 
culminating in the γ-secretase-medi-
ated proteolytic release of the intra-
cellular fragment of NOTCH1 (ICN). 
The ICN then translocates to the 
nucleus, where it is transcriptionally 
active and required for T cell devel-
opment (reviewed in Grabher et al., 
2006). Aberrant NOTCH1 activation 
leads to T-ALL in the mouse, and 
nOTcH and PI3K
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Constitutive signaling by the NO
acute lymphoblastic leukemia (T-
γ-secretase inhibitors (GSIs) fails
receptor. A recent report by Palo
event leading to resistance to NO
from the NOTCH1 to the PI3K/AK
ously inhibit both pathways as a authors have set the stage for DCIS, 
which is generally a segmental disease 
(Figure 1). Perhaps this will also be the 
spur to study lobular carcinoma in situ 
(LCIS), a multifocal proliferation with 
a bilateral risk of invasive carcinoma, 
and hence an even bigger dilemma 
regarding appropriate management.
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report in Nature Medicine, Palomero 
et al. (2007) show that homozygous 
loss of PTEN is a critical determinant 
of resistance to GSI-mediated inhi-
bition of NOTCH1 signaling in T-ALL 
cell lines (Figure 1). They show fur-
ther that PTEN expression is nega-
tively regulated by HES1, a prominent 
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